4//SEC Filing
Paggiarino Dario A. 4
Accession 0001562180-24-003193
CIK 0001314102other
Filed
Apr 1, 8:00 PM ET
Accepted
Apr 2, 5:27 PM ET
Size
19.6 KB
Accession
0001562180-24-003193
Insider Transaction Report
Form 4
Paggiarino Dario A.
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2024-03-30+5,834→ 48,056 total - Exercise/Conversion
Restricted Stock Units
2024-03-30−30,570→ 0 totalExercise: $0.00→ Common Stock (30,570 underlying) - Exercise/Conversion
Restricted Stock Units
2024-03-30−14,000→ 0 totalExercise: $0.00→ Common Stock (14,000 underlying) - Exercise/Conversion
Restricted Stock Units
2024-03-30−5,834→ 0 totalExercise: $0.00→ Common Stock (5,834 underlying) - Exercise/Conversion
Common Stock
2024-03-30+30,570→ 78,626 total - Exercise/Conversion
Common Stock
2024-03-30+14,000→ 92,626 total - Tax Payment
Common Stock
2024-03-30$20.67/sh−15,493$320,240→ 77,133 total - Tax Payment
Common Stock
2024-03-30$20.67/sh−2,957$61,121→ 74,176 total - Tax Payment
Common Stock
2024-03-30$20.67/sh−7,096$146,674→ 67,080 total
Footnotes (4)
- [F1]No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
- [F2]The restricted stock units will vest in three ratable annual installments beginning January 6, 2024.
- [F3]The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.
- [F4]The restricted stock units will vest in three ratable annual installments beginning January 5, 2025.
Documents
Issuer
EyePoint Pharmaceuticals, Inc.
CIK 0001314102
Entity typeother
Related Parties
1- filerCIK 0001574261
Filing Metadata
- Form type
- 4
- Filed
- Apr 1, 8:00 PM ET
- Accepted
- Apr 2, 5:27 PM ET
- Size
- 19.6 KB